Products & Solutions
Science from Nature, Solutions for Tomorrow. 
Filter:
[en]AKNUTR® [/en]Nutrition
[en]AKCOS® [/en]Personal Care
[en]AKTINPHARM® [/en]Pharmaceutical
APIs & Intermediates
[en]AkVEri® [/en]Life Science Reagents
Intermediates

                    
Current Filters261Product
Guggulsterone

Cat. No.

AKA-342

CAS No.

95975-55-6

MF

C21H28O2

MW

312.4

Guggulsterone is a plant sterol.
Fmoc-Asn(Trt)- Asn(Trt)-OH

Cat. No.

AKA-343

CAS No.

844641-64-1

MF

C61H52N4O7

MW

953.1

Fmoc-Asn(Trt)-Asn(Trt)-OH is a doubly protected asparagine-asparagine dipeptide in which the alpha-amino group is protected by Fmoc and both side-chain amides are protected by trityl (Trt) groups, used as a protected dipeptide building block for solid-phase peptide synthesis.
D-Menthol

Cat. No.

AKA-344

CAS No.

15356-60-2

MF

C10H20O

MW

156.27

(+)-Menthol (Standard) is an analytical standard of (+)-Menthol, intended for research and analytical applications.
Lenacapavir sodium Intermediate (N-1)

Cat. No.

AKA-346

CAS No.

2189684-58-8

MF

C40H34ClF10N7O7S3

MW

1046.38

Lenacapavir Sodium Intermediate (N-1) is a key intermediate of lenacapavir sodium.
5-Vinylpyrrolidone (5-VP)

Cat. No.

AKA-348

CAS No.

7529-16-0

MF

C6H9NO

MW

111.14

5-Vinyl-2-pyrrolidone is a specific pyrrolidone derivative.
Catharanthine Tartrate

Cat. No.

AKA-356

CAS No.

4168-17-6

MF

2(C21H24N2O2).C4H6O6

MW

822.94

Catharanthine Tartrate is a component of the Vinca alkaloids and inhibits voltage-gated L-type calcium channels (VOCC).
Pentosan Polysulfate

Cat. No.

AKA-357

CAS No.

37300-21-3

MF

(C5H10O14S2) N

MW

4000-6000

Pentosan polysulfate is a semi-synthetic bioactive polysaccharide derivative that can be used as an intermediate for the synthesis of specific sulfated polysaccharide derivatives. Its degree of sulfation and molecular weight characteristics make it suitable for further chemical modification.
Pentosan polysulfate sodium

Cat. No.

AKA-358

CAS No.

140207-93-8

MF

(C5H10O14S2NA2) N

MW

4000-6000

Pentosan polysulfate sodium is a bioavailable semi-synthetic molecule with anti-inflammatory, chondrogenic, and anti-HIV activities for interstitial cystitis research.
Dipexion™ Fmoc-Ala-Thr[PSI(Me,Me)Pro]-OH

Cat. No.

AKA-361

CAS No.

252554-79-3

MF

C25H28N2O6

MW

452.5

Dipexion™ Fmoc-Ala-Thr[PSI(Me,Me)Pro]-OH is a dipeptide used in Fmoc solid-phase peptide synthesis research and development to reduce peptide chain aggregation and improve the quality of crude peptides.
Dipexion™ Fmoc-Ser(tBu)-Ser[PSI(Me,Me)Pro]-OH

Cat. No.

AKA-362

CAS No.

1000164-43-1

MF

C28H34N2O7

MW

510.58

Dipexion™ Fmoc-Ser(tBu)-Ser[PSI(Me,Me)Pro]-OH is a dipeptide used in Fmoc solid-phase peptide synthesis research and development to reduce peptide chain aggregation and improve the quality of crude peptides.
Dipexion™ Fmoc-Thr(tBu)-Ser[PSI(Me,Me)Pro]-OH

Cat. No.

AKA-363

CAS No.

1425938-63-1

MF

C29H36N2O7

MW

524.61

Dipexion™ Fmoc-Thr(tBu)-Ser[PSI(Me,Me)Pro]-OH is a dipeptide used in Fmoc solid-phase peptide synthesis research and development to reduce peptide chain aggregation and improve the quality of crude peptides.
Dipexion™ Fmoc-Lys(Boc)-Ser[PSI(Me,Me)Pro]-OH

Cat. No.

AKA-364

CAS No.

957780-54-0

MF

C32H41N3O8

MW

595.68

Dipexion™ Fmoc-Lys(Boc)-Ser[PSI(Me,Me)Pro]-OH is a dipeptide used in Fmoc solid-phase peptide synthesis research and development to reduce peptide chain aggregation and improve the quality of crude peptides.
Dipexion™ Fmoc-Glu(OtBu)-Thr[PSI(Me,Me)Pro]-OH

Cat. No.

AKA-365

CAS No.

957780-56-2

MF

C31H38N2O8

MW

566.64

Dipexion™ Fmoc-Glu(OtBu)-Thr[PSI(Me,Me)Pro]-OH is a dipeptide used in Fmoc solid-phase peptide synthesis research and development to reduce peptide chain aggregation and improve the quality of crude peptides.
Dipexion™ Fmoc-Ser(tBu)-Thr[PSI(Me,Me)Pro]-OH

Cat. No.

AKA-366

CAS No.

1266350-99-5

MF

C29H36N2O7

MW

524.61

Dipexion™ Fmoc-Ser(tBu)-Thr[PSI(Me,Me)Pro]-OH is a dipeptide used in Fmoc solid-phase peptide synthesis research and development to reduce peptide chain aggregation and improve the quality of crude peptides.
Dipexion™ Fmoc-Leu-Ser[PSI(Me,Me)Pro]-OH

Cat. No.

AKA-367

CAS No.

339531-50-9

MF

C27H32N2O6

MW

480.55

Dipexion™ Fmoc-Leu-Ser[PSI(Me,Me)Pro]-OH is a dipeptide suitable for use as a structural perturbation tool in Fmoc solid-phase peptide synthesis research and development.
Dipexion™ Fmoc-Lys(Boc)-Thr[PSI(Me,Me)Pro]-OH

Cat. No.

AKA-368

CAS No.

911838-56-7

MF

C33H43N3O8

MW

609.71

Dipexion™ Fmoc-Lys(Boc)-Thr[PSI(Me,Me)Pro]-OH is a dipeptide used in Fmoc solid-phase peptide synthesis research and development to reduce peptide chain aggregation and improve the quality of crude peptides.
Cart
TotalProducts
Request Quote
  • China
  • Afghanistan
  • Albania
  • Algeria
  • Andorra
  • Angola
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Brazil
  • Brunei
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Central African Republic
  • Chad
  • Chile
  • Colombia
  • Comoros
  • Congo (Brazzaville)
  • Congo (Kinshasa)
  • Cook Islands
  • Costa Rica
  • Côte d'Ivoire
  • Croatia
  • Cuba
  • Cyprus
  • Czech Republic
  • Denmark
  • Djibouti
  • Dominica
  • Dominican Republic
  • East Timor (Timor-Leste)
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Eswatini
  • Ethiopia
  • Fiji
  • Finland
  • France
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Greece
  • Grenada
  • Guatemala
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Honduras
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • South Korea
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Libya
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Mauritania
  • Mauritius
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Morocco
  • Mozambique
  • Myanmar (Burma)
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • North Macedonia
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Qatar
  • Romania
  • Russia
  • Rwanda
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Vincent and the Grenadines
  • Samoa
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • Spain
  • Sri Lanka
  • Sudan
  • South Sudan
  • Suriname
  • Sweden
  • Switzerland
  • Syria
  • Tajikistan
  • Tanzania
  • Thailand
  • Togo
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates (UAE)
  • United Kingdom (UK)
  • United States (US)
  • Uruguay
  • Uzbekistan
  • Vanuatu
  • Vatican City
  • Venezuela
  • Vietnam
  • Yemen
  • Zambia
  • Zimbabwe
  • Beijing-Beijing
  • Tianjin-Tianjin
  • Hebei-Shijiazhuang
  • Shanxi-Taiyuan
  • Inner Mongolia-Hohhot
  • Liaoning-Shenyang
  • Jilin-Changchun
  • Heilongjiang-Harbin
  • Shanghai-Shanghai
  • Jiangsu-Nanjing
  • Zhejiang-Hangzhou
  • Anhui-Hefei
  • Fujian-Fuzhou
  • Jiangxi-Nanchang
  • Shandong-Jinan
  • Henan-Zhengzhou
  • Hubei-Wuhan
  • Hunan-Changsha
  • Guangdong-Guangzhou
  • Guangxi-Nanning
  • Hainan-Haikou
  • Chongqing-Chongqing
  • Sichuan-Chengdu
  • Guizhou-Guiyang
  • Yunnan-Kunming
  • Tibet-Lhasa
  • Shaanxi-Xi'an
  • Gansu-Lanzhou
  • Qinghai-Xining
  • Ningxia-Yinchuan
  • Xinjiang-Urumqi
  • Hong Kong-Hong Kong
  • Macao-Macao
  • Taiwan-Taipei